For the Inventor, By the Inventor

Enter assignee name

Newark, NJ, United States of America

The Public Health Research Institute of the City of New York, Inc.

USPTO Granted Patents = 29

CIPO Patents = 2

Forward Citations = 2,198

Loading Chart...

Loading Chart...

47 inventors (with patents filed for the assignee):

Fred Russell Kramer (14 out of 36 patents)

Sanjay Tyagi (10 out of 24 patents)

Abraham Pinter (5 out of 14 patents)

4. Paul M Lizardi (5 out of 32 patents)

5. Karl A Drlica (4 out of 4 patents)

6. Peter Blackburn (2 out of 20 patents)

7. Konstantin P Lyashchenko (2 out of 2 patents)

8. Yuzhi Dong (2 out of 2 patents)

9. Xilin Zhao (2 out of 2 patents)

10. Maria Laura Gennaro (2 out of 25 patents)

11. Sara-Ann Gusik (2 out of 6 patents)

12. June Polak (2 out of 8 patents)

13. Stephen D Rubino (2 out of 6 patents)

14. Ulf D Landegren (2 out of 2 patents)

15. Samuel Kayman (2 out of 2 patents)

29 patents: Sort by Forward Citations

1. 7799522 - Specific double-stranded probes for homogeneous detection of nucleic acid and their application methods (2010-09-21),

2. 7741031 - Optically decodable microcarries, arrays and methods (2010-06-22),

3. 7385043 - Homogeneous multiplex screening assays and kits (2008-06-10),

4. 7313482 - Selection of target sites for antisense attack of RNA (2007-12-25),

5. 7129087 - Oligonucleotide-facilitated coalescence (2006-10-31),

6. 7097810 - Delivery of metered amounts of liquid materials (2006-08-29),

7. 6815201 - HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies (2004-11-09),

8. 6596281 - Mycobacterium tuberculosis specific proteins and genes, mixtures of antigens and uses thereof (2003-07-22),

9. 6461817 - Non-competitive co-amplification methods (2002-10-08),

10. 6406881 - Dosing and development of antimicrobial and antiviral drugs determined by restriction of resistant mutant selection (2002-06-18),

11. 6365729 - High specificity primers, amplification methods and kits (2002-04-02),

12. 6322971 - Oligonucleotide arrays and their use for sorting, isolating, sequencing, and manipulating nucleic acids (2001-11-27),

13. 6265181 - Dosing and development of antimicrobial and antiviral drugs determined by restriction of resistant mutant selection (2001-07-24),

14. 6150097 - Nucleic acid detection probes having non-FRET fluorescence quenching and (2000-11-21),

15. 6103476 - Detectably labeled, dual conformation oligonucleotide probes, assays and (2000-08-15),

The Public Health Research Institute of the City of New York, Inc. (PHRI) is a renowned biomedical research organization dedicated to advancing public health and reducing the burden of infectious diseases. With a multidisciplinary approach, PHRI conducts innovative research, fosters scientific collaborations, and translates discoveries into practical applications. Through collaborations with academia, industry, and government, PHRI strives to improve global health outcomes and address emerging challenges in infectious diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

29 Patents

#5 in Newark, NJ

#457 in New Jersey

#11,219 in US

#21,844 in the World

Newark, NJ, United States of America

The Public Health Research Institute of the City of New York, Inc.

Forward Citations = 2,198

47 inventors:

Fred Russell Kramer (14 out of 36 patents)

Sanjay Tyagi (10 out of 24 patents)

Abraham Pinter (5 out of 14 patents)

4. Paul M Lizardi (5 out of 32 patents)

5. Karl A Drlica (4 out of 4 patents)

Please report any incorrect information to support@idiyas.com

Loading…